Newbridge Financial Services Group Inc. Decreases Stock Position in Omeros Corporation $OMER

Newbridge Financial Services Group Inc. reduced its holdings in shares of Omeros Corporation (NASDAQ:OMER) by 74.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 34,310 shares of the biopharmaceutical company’s stock after selling 100,200 shares during the period. Newbridge Financial Services Group Inc.’s holdings in Omeros were worth $589,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in OMER. Acadian Asset Management LLC purchased a new position in shares of Omeros during the 1st quarter valued at approximately $357,000. XTX Topco Ltd purchased a new position in shares of Omeros during the 2nd quarter valued at approximately $191,000. Invesco Ltd. boosted its stake in shares of Omeros by 34.1% during the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 29,644 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after buying an additional 97,224 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Omeros during the 2nd quarter valued at approximately $40,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Trading Up 0.8%

OMER stock opened at $10.98 on Wednesday. The firm has a market cap of $790.56 million, a P/E ratio of -21.96 and a beta of 2.53. Omeros Corporation has a 12-month low of $2.95 and a 12-month high of $17.65. The stock’s 50 day simple moving average is $11.31 and its 200 day simple moving average is $10.01.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $3.69. On average, research analysts forecast that Omeros Corporation will post -3.09 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Wall Street Zen upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Research upgraded Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. HC Wainwright increased their target price on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.33.

Insider Activity

In related news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 12.90% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.